methylprednisolone, Drugs Monitor

(26 May 2021) Methylprednisolone- high dose statistically significantly decreased the recovery time

May 28, 2021

Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia https://doi.org/10.1371/journal.pone.0252057 216 patients had Covid-19 pneumonia documented by ground-glass imaging and alveolar pressure / inspired oxygen fraction (PaFi) less than 300. 111 patients received dexamethasone (DXM) and 105 received methylprednisolone (MTP). Patients… Continue reading "(26 May 2021) Methylprednisolone- high dose statistically significantly decreased the recovery time"

(23 May 2021) Methyl prednisolone- early high dose reduced mortality, length of hospitalization

May 28, 2021

Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis https://doi.org/10.1016/j.advms.2021.04.002 This is a single-center, retrospective study considering the patients with confirmed COVID-19 pneumonia admitted to our hospital between 9th March and 15(th) June… Continue reading "(23 May 2021) Methyl prednisolone- early high dose reduced mortality, length of hospitalization"

(12 Apr 2021) Methylprednisolone- demonstrated better results compared to dexamethasone in hypoxic patients

April 29, 2021

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial https://doi.org/10.1186/s12879-021-06045-3 IRCT20200204046369N1- In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020,… Continue reading "(12 Apr 2021) Methylprednisolone- demonstrated better results compared to dexamethasone in hypoxic patients"

(09 Mar 2021) Methylprednisolone- Survival at 28 days was 98.6%

April 7, 2021

Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19 https://www.medrxiv.org/content/10.1101/2021.03.08.21253117v1 NCT04355247 -Eligible patients were those 21 years or older with a diagnosis of Covid-19 and oxygen saturation ≥91%. For patients to… Continue reading "(09 Mar 2021) Methylprednisolone- Survival at 28 days was 98.6%"

(05 Feb 2021) Methylprednisolone- decreased mortality as compared to dexamethasone

February 16, 2021

A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients with COVID-19 https://www.medrxiv.org/content/10.1101/2021.02.03.21251088v1 This study retrospectively compares the effectiveness of methylprednisolone to dexamethasone in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) requiring ICU care. A total… Continue reading "(05 Feb 2021) Methylprednisolone- decreased mortality as compared to dexamethasone"

(16 Jan 2021) Lopinavir/Ritonavir (LPV/r), Arbidol (ARB) and Methylprednisolone -LPV/r combined with ARB no effect,

January 19, 2021

Clinical efficacy of Methylprednisolone and the combined use of Lopinavir/Ritonavir with Arbidol in treatment of Coronavirus Disease 2019 https://doi.org/10.1002/jmv.26798 For all patients, there were no significant differences in the change of body temperature, the time for negative conversion and hospital… Continue reading "(16 Jan 2021) Lopinavir/Ritonavir (LPV/r), Arbidol (ARB) and Methylprednisolone -LPV/r combined with ARB no effect,"

(22 Dec 2020) Methylprednisolone- did not improve prognosis in severe and critical COVID-19 patients

December 28, 2020

Effect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases https://doi.org/10.12998/wjcc.v8.i23.5952 A total of 102 severe and critically ill COVID-19 patients were included in this study. They were divided into treatment (69, 67.6%) and control groups (33, 32.4%)… Continue reading "(22 Dec 2020) Methylprednisolone- did not improve prognosis in severe and critical COVID-19 patients"

(20 Dec 2020) Methylprednisolone- early use in ICU patients not recommended

December 28, 2020

Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study https://doi.org/10.1186/s13054-020-03429-w Out of the 294 critically ill patients affected by COVID-19, 183 (62.2%) received corticosteroids, with methylprednisolone as the most frequently administered corticosteroid (175 accounting for 96%). Of… Continue reading "(20 Dec 2020) Methylprednisolone- early use in ICU patients not recommended"

(22 Nov 2020) Anakinra, Methylprednisolone- Combination beneficial for hyperinflammation and respiratory failure

November 27, 2020

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study https://doi.org/10.1016/j.jaci.2020.11.006 120 COVID-19 patients with hyperinflammation (median age 62 years, 80.0% males, median PaO2:FiO2 ratio 151, 32.5% on mechanical ventilation) were evaluated. Of these,… Continue reading "(22 Nov 2020) Anakinra, Methylprednisolone- Combination beneficial for hyperinflammation and respiratory failure"

Tag: methylprednisolone